Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12610000381088
Ethics application status
Approved
Date submitted
4/05/2010
Date registered
12/05/2010
Date last updated
19/11/2018
Date data sharing statement initially provided
19/11/2018
Type of registration
Prospectively registered
Titles & IDs
Public title
The Kava & Anxiety Lowering Medication (KALM) study
Query!
Scientific title
Examining the effects of administration of Kava on anxiety versus placebo in adults aged 18-65 presenting with Generalized Anxiety Disorder (GAD).
Query!
Secondary ID [1]
251691
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
KALM Study
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Anxiety
257283
0
Query!
Mood
257284
0
Query!
Condition category
Condition code
Mental Health
257430
257430
0
0
Query!
Anxiety
Query!
Alternative and Complementary Medicine
257431
257431
0
0
Query!
Other alternative and complementary medicine
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Each participant will be required to consume 1 dose of Kava tablets (120mg of kavalactones) or 1 dose of Placebo tablets. The placebo tablets are made from microcellulose and are identical in taste and appearance to their active counterpart.
Interventions used for the first 3 weeks of the controlled phase of the trial: Group 1) 1 Kava tablet prescribed twice per day (standardised for 120 mg of kavalactones per day: active constituent); Group 2) 1 placebo tablet twice per day.
Before randomisation occurs, a one week placebo run-in will be employed, with any responders having a >50% reduction on the Hamilton Anxiety Scale (HAM-A) to be excluded.
After 3 weeks of the controlled phase, non-responders will be given an extra tablet (a doubling of the dose- either double placebo or 240mg of Kava: still within TGA recommended dosage range). All participants will be switched to placebo during Week 8 to observe any occurrence of rebound anxiety or withdrawal symptoms.
Query!
Intervention code [1]
256420
0
Treatment: Drugs
Query!
Comparator / control treatment
As mentioned above one group will receive placebo tablets throughout the study.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
258351
0
Evaluate the efficacy and safety of Kava monotherapy compared to Placebo in General Anxiety Disorder (GAD).
This will be assessed by (a)Structured Clinical Interview for Diagnostic and Stastical Manual for mental Disorders (DSM) disorders (automated version) b) Hamiton Anxiety Scale (HAM-A) (primary outcome) c) Montgomery-Asberg Depression Rating Scale (MADRS) d) Weekly safety checklists (for adverse reactions) e) The Arizona Sexual Experience Scale (ASEX) to assess the difference in sexual dysfunction between placebo and Kava. f) Addiction assessment scale to observe whether any perceived addictiveness to the intervention is occurring g) Three blood tests (liver function test and a genetic test providing information on liver enzyme function and neurochemistry).
Query!
Assessment method [1]
258351
0
Query!
Timepoint [1]
258351
0
Data collection will occur during week 0 at baseline and at weeks 1,2,4,7,8.
Query!
Primary outcome [2]
258352
0
Compare Kava at 240mg and 120mg of kavalactones to determine any differences in efficacy.
This will be assessed by (a)Structured Clinical Interview for DSM disorders (automated version) b) HAM-A (primary outcome) c) MADRS d) Weekly safety checklists (for adverse reactions) e) The Arizona Sexual Experience Scale (ASEX) to assess the difference in sexual dysfunction between paroxetine, placebo, and Kava. f) Addiction assessment scale to observe whether any perceived addictiveness to the interventions is occurring g) Three blood tests (liver function test and a genetic test providing information on liver enzyme function and neurochemistry).
Query!
Assessment method [2]
258352
0
Query!
Timepoint [2]
258352
0
Data collection will occur during week 0 at baseline and at weeks 1,2,4,7,8.
Query!
Secondary outcome [1]
264087
0
Assess any differences between responders or non-responders to Kava due to genetic differences (liver enzyme or neurochemical polymorphisms).
Genetic tests exploring polymorphisms of liver enzyme DNA (cytochrome P450 2D6 and 3A4, and brain chemical DNA (GABA receptors and transporters, noradrenaline and serotonin transporters, Val158Met) holds the potential to determine genetic profiles of responders and non-responders.
Query!
Assessment method [1]
264087
0
Query!
Timepoint [1]
264087
0
Data collection will occur during week 0 at baseline and at weeks 1 and 7.
Query!
Eligibility
Key inclusion criteria
Any person aged 18-65 presenting with a structured clinical interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Structured Clinical Interview for DSM (SCID) diagnosed GAD, and a HAM-A of >14.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Primary diagnosis other than GAD; Psychotic or Bipolar illness; Significant suicidal ideation in the previous 6 months; antidepressant, mood stabiliser, antipsychotic, opiod analgesics, St John’s wort, Human immunodeficiency virus (HIV), anti-tumoral/cancer, blood pressure, warfarin, Parkinson’s, epileptic, migraine or anti-ulcer medication; Diagnosed hepato-biliary disease/inflammation (or elevated liver enzymes at Baseline blood test); Thyroid disease (or thyroid hormone abnormality at baseline blood test); DSM-IV diagnosed substance abuse or dependency disorder including alcohol in the previous 6 months; Regular use of Kava in the previous 12 months; Previous adverse reaction to Kava; Seeing a psychologist or counsellor currently or in the previous month; Pregnancy or trying to conceive; Lack of facility in written or spoken English; Montgomery-Asberg Depression Rating Scale (MADRS) score of >18.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be contacted via avertisements in health clinics and on community notice boards. Participants will be screened to ensure they pass the inclusion/exclusion criteria and allocated a participant number and treatment condition. The person who determines if a participant is eleigible for participation will be unaware, when the decision is made, to which group the participant will be allocated to. Allocation concealment was performed using numbered containers.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A disinterested third party generated the randomisation list using a computerised random number sequence generator. Participants were allocated to receive 1 of 2 treatments. Allocation involved contacting the holder of the allocation schedule who is off-site.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Participants who are non-responders in the first 3 weeks of treatment will have their number of tablets taken per day doubled.
Query!
Phase
Phase 3 / Phase 4
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/03/2011
Query!
Actual
12/04/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
20/12/2011
Query!
Date of last data collection
Anticipated
Query!
Actual
22/02/2012
Query!
Sample size
Target
160
Query!
Accrual to date
Query!
Final
75
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Funding & Sponsors
Funding source category [1]
256906
0
Commercial sector/Industry
Query!
Name [1]
256906
0
Integria
Query!
Address [1]
256906
0
Level 1, 8
Clunies Ross Court, Eight Mile Plains Qld 4300
Query!
Country [1]
256906
0
Australia
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Integria
Query!
Address
Level 1, 8
Clunies Ross Court, Eight Mile Plains Qld 4300
Query!
Country
Australia
Query!
Secondary sponsor category [1]
256178
0
None
Query!
Name [1]
256178
0
Query!
Address [1]
256178
0
Query!
Country [1]
256178
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
258916
0
The Melbourne Clinic Research Ethics Committee
Query!
Ethics committee address [1]
258916
0
130 Church Street RICHMOND VIC 3121
Query!
Ethics committee country [1]
258916
0
Australia
Query!
Date submitted for ethics approval [1]
258916
0
01/01/2010
Query!
Approval date [1]
258916
0
11/03/2010
Query!
Ethics approval number [1]
258916
0
182
Query!
Ethics committee name [2]
267106
0
Human Research Ethics Committee, Swinburne University.
Query!
Ethics committee address [2]
267106
0
Level 7, 60 William Street Hawthorn Campus swinburne University
Query!
Ethics committee country [2]
267106
0
Australia
Query!
Date submitted for ethics approval [2]
267106
0
Query!
Approval date [2]
267106
0
15/01/2011
Query!
Ethics approval number [2]
267106
0
2010/254
Query!
Summary
Brief summary
The design of the study is a phase IV, 2-arm, 8-week, randomised, double-blind, placebo-controlled trial using one 3.2 gram tablet of Kava (Piper methysticum), twice per day equal to 120mg of kavalactones (but in non-responders at week 3 this will be doubled to two tablets twice per day equal to 240mg of kavalactones), or matching placebo, in 100 currently anxious participants with diagnosed generalised anxiety disorder (GAD). Participants are required to fill out assessment forms throughout the study and to have 3 blood tests (liver function tests and a genetic test providing information on liver enzyme function and neurochemistry). Assessment will occur at Healthscope hospital sites in Victoria and at Swinburne University of Technology, Hawthorn VIC. Data collection will occur during week 0 at baseline and at weeks 1,2,4,7,8 by trained research assistants. Assessment tools used: Compulsory a) Structured Clinical Interview for DSM disorders (automated version) b) HAM-A (primary outcome) c) MADRS d) Weekly safety checklists (for adverse reactions) e) Current health & medications questionnaire to assess their current health and any medications they are currently taking f) Drug Check to assess alcohol and other drug use g) Demographics questionnaire to assess age, education, marital status, employment h) The Arizona Sexual Experience Scale (ASEX) to assess the difference in sexual dysfunction between paroxetine, placebo, and Kava. i) Addiction assessment scale to observe whether any perceived addictiveness to the interventions is occurring j) Three blood tests (liver function test and a genetic test providing information on liver enzyme function and neurochemistry). Participants will be required to attend 6 visits at the Brain Science Institute, Hawthorn. The first visit is a baseline session. Participants will be asked to complete all tests: screening assessments, consent forms, mood and anxiety questionnaires. Testing for all subsequent visits will follow the same outline of their baseline session (excluding consent forms and including an adverse effects safety questionnaire). Participants will be given $100 each at the completion of the study to compensate for their time and to cover travel expenses if required. The recruitment, data collection and analysis period will be approximately 1 year. Data will be analysed by research team using SPSS 17.0. Repeated measures ANOVAs will be used to assess any changes between groups across time.
Query!
Trial website
TBA
Query!
Trial related presentations / publications
None
Query!
Public notes
Query!
Contacts
Principal investigator
Name
31122
0
Query!
Address
31122
0
Query!
Country
31122
0
Query!
Phone
31122
0
Query!
Fax
31122
0
Query!
Email
31122
0
Query!
Contact person for public queries
Name
14369
0
Jerome Sarris
Query!
Address
14369
0
The Melbourne Clinic
130 Church St, Richmond
Victoria, 3121
Query!
Country
14369
0
Australia
Query!
Phone
14369
0
+613 9420 9350
Query!
Fax
14369
0
Query!
Email
14369
0
[email protected]
Query!
Contact person for scientific queries
Name
5297
0
Jerome Sarris
Query!
Address
5297
0
The Melbourne Clinic
130 Church St, Richmond
Victoria, 3121
Query!
Country
5297
0
Australia
Query!
Phone
5297
0
+613 9420 9350
Query!
Fax
5297
0
Query!
Email
5297
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF